Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after...

por Castro, Januario E., Lengerke-Diaz, Paula A., Velez Lujan, Juliana, Choi, Michael Y., Moreno-Cortes, Eider F., Forero, Jose V., Garcia-Robledo, Juan Esteban, Jacobs, Chaja, McCarthy, Colin, Heinen, Alaina, Amaya-Chanaga, Carlos I., Kipps, Thomas J.
Publicado 2022